H-151 attenuates lipopolysaccharide-induced acute kidney injury by inhibiting the STING–TBK1 pathway

Lei Xia,Jia-hui Jiang,Jie-yu Liu,Tian-yi Zhang,Yu-xin Dong,Qi-hui Liu,Yan-Fen Chai,Yan-cun Liu,Song-tao Shou
DOI: https://doi.org/10.1080/0886022x.2024.2363591
IF: 3.222
2024-06-12
Renal Failure
Abstract:Sepsis is a severe systemic infectious disease that often leads to multi-organ dysfunction. One of the common and serious complications of sepsis is renal injury. In this study, we aimed to investigate the potential mechanistic role of a novel compound called H-151 in septic kidney injury. We also examined its impact on renal function and mouse survival rates. Initially, we confirmed abnormal activation of the STING–TBK1 signaling pathway in the kidneys of septic mice. Subsequently, we treated the mice with H-151 and observed significant improvement in sepsis-induced renal dysfunction. This was evidenced by reductions in blood creatinine and urea nitrogen levels, as well as a marked decrease in inflammatory cytokine levels. Furthermore, H-151 substantially improved the seven-day survival rate of septic mice, indicating its therapeutic potential. Importantly, H-151 also exhibited an inhibitory effect on renal apoptosis levels, further highlighting its mechanism of protecting against septic kidney injury. These study findings not only offer new insights into the treatment of septic renal injury but also provide crucial clues for further investigations into the regulatory mechanisms of the STING–TBK1 signaling pathway and potential drug targets.
urology & nephrology
What problem does this paper attempt to address?
The paper primarily investigates the potential mechanisms of action of the H-151 compound in treating acute kidney injury (AKI) induced by lipopolysaccharide (LPS). The study focuses on the alleviating effects of H-151 on acute kidney injury by inhibiting the STING–TBK1 signaling pathway. Specifically, the research found that LPS can activate the STING–TBK1 pathway in mouse kidneys, leading to renal dysfunction, elevated levels of inflammatory factors, and increased cell apoptosis, thereby causing acute kidney injury. As an inhibitor of STING, H-151 can significantly suppress the expression of STING protein and the phosphorylation of TBK1, thereby reducing inflammatory responses, lowering serum creatinine and urea nitrogen levels, alleviating renal tissue pathological changes, decreasing cell apoptosis, and improving the seven-day survival rate of mice with LPS-induced acute kidney injury. Therefore, H-151 may be a potential effective drug for the treatment of acute kidney injury mediated by the STING–TBK1 pathway. The study also indicates that H-151 can further inhibit the activation of this pathway by downregulating STING mRNA levels, suggesting its potential application in treating diseases related to STING–TBK1. In summary, the paper aims to reveal the mechanisms by which H-151 counteracts LPS-induced acute kidney injury by inhibiting the STING–TBK1 signaling pathway, providing a new perspective and potential drug targets for the treatment of acute kidney injury.